一、基本情况
赵忠熙，药剂学专业博士生导师。近五年，先后主持国家“973”计划和艾滋病和病毒性肝炎等重大传染病防治国家科技重大专项课题各1项、省部级课题共4项；获国家发明专利授权4项；发表SCI收录学术论文35篇。
二、主要研究方向
1.新药创制：用于治疗呼吸系统疾病和肿瘤的小分子免疫治疗药物的研发。
2.中药大品种再开发：用于治疗肺结核、肺癌、糖尿病肾病、慢阻肺等中药免疫治疗药物的再开发。
3.药剂学研究：吸入、缓控释、靶向纳米、膜制剂等新型给药系统关键技术和相关产品的研究；高端制剂仿制药一致性评价研究。
4.创新医疗器械:用于呼吸系统疾病防治的呼吸治疗仪及配套产品开发。
三、承担重大课题
1. 1.1类抗胃癌新药“CPD0012”和抗肺癌复方新药“CPD0004/200”临床前研究：横向项目（经费620万元，在研）；
2.治疗耐药肺结核中药复方益肺通络方物质基础、免疫作用机制研究及相关中药大品种再开发：国家科技重大专项课题（经费102万元，2013-2017年）、抗肺癌中药大品种再开发（在研）；
3.治疗耐药肺结核和肺癌创新医疗器械及配套产品产学研开发：山东省急需紧缺人才项目（经费75万元，2016-2017年）、横向项目（经费500万元，在研）；
4.红枣和大蒜物质基础和作用机制研究以及相关保健品和特医食品产学研开发：国家“973”计划课题（经费60万元，2012-2014年）、山东省农业成果转化项目（经费100万元，2014-2017年）、山东省急需紧缺人才项目（经费20万元，2015-2016年）、横向项目（经费1100万元，在研）。
四、代表性学术论文（10篇代表性成果）
1. Y. Liu, A. Li, X. Feng, X. Jiang, X. Sun, W. Huang, X. Zhu, Z. Zhao,L-menthol alleviates cigarette smoke extract induced lung injury in rats by inhibiting oxidative stress and inflammation via nuclear factor kappa b, p38 MAPK and Nrf2 signalling pathways, RSC Adv., 2018, 8,9353.
2. X. Jiang, X. Zhu, N. Liu, H. Xu, Z. Zhao, S. Li, S. Li, J. Cai and J. Cao, Diallyltrisulfide inhibits growth of NCI-H460 in vitro and in vivo, and ameliorates cisplatin-induced oxidative injury in the treatment of lung Carcinoma,Int. J. Biol. Sci., 2017, 13, 167-178.
3. X. Jiang, X. Zhu, W. Huang, H. Xu, Z. Zhao, S. Li, S. Li, J. Cai, J. Cao, Garlic-derived organosulfur compound exerts antitumor efficacy via activation of MAPK pathway and modulation of cytokines in SGC-7901 tumor-bearing mice, Int. Immunopharm., 2017, 48, 135–145.
4. X. Zhu, X. Jiang, A. Li, Z. Zhao and S. Li, S-Allylmercaptocysteine Attenuates Cisplatin-Induced Nephrotoxicity through Suppression of Apoptosis, Oxidative Stress, and Inflammation, Nutrients, 2017, 9, 166.
5. X. Zhu, X. Jiang, C. Duan, A. Li, Y. Sun, Q. Qi, Y. Liu, S. Li and Z. Zhao, S-Allylmercaptocysteine induces G2/M phase arrest and apoptosis via ROS-mediated p38 and JNK signaling pathway in human colon cancer cells in vitro and in vivo, RSC Adv., 2017, 7, 49151.
6. X. Zhu, X. Jiang, A. Li, Y. Sun, Y. Liu, X. Sun, X. Feng, S. Li, and Z. Zhao, S-allylmercaptocysteine suppresses the growth of human gastric cancer xenografts through induction of apoptosis and regulation of MAPK and PI3K/Akt signaling pathways,Biochem. Biophys. Res. Commun., 2017, 492, 1-6.
7. M. Yang, Z. Dong, Y. Zhang, F. Zhang, Y. Wang and Z. Zhao, Preparation and evaluation of posaconazole-loaded enteric microparticles in rats, Drug Dev. Ind. Pharm., 2017, 43, 618–627.
8. Y. Wang, W. Huang, J. Zhang, M. Yang, Q. Qi, K. Wang, Z. Zhao,The therapeutic effect of Bletilla striata extracts on LPS-induced acute lung injury by the regulations of inflammation and oxidation, RSC Adv., 2016, 6, 89338.
9. Y. Wang, Q. Qi, A. Li, M. Yang, W. Huang, H. Xu, Z. Zhao, and S. Li, Immuno-enhancement effects of YifeiTongluo Granules on cyclophosphamide-induced immunosuppression in Balbc mice, J. Ethnopharmacol., 2016, 194, 72–82.
10. Y. Wang, X. Liu, G. Liu, H. Guo, C. Li, Y. Zhang, F. Zhang, Z. Zhao, H. Cheng, Novel galactosylated biodegradable nanoparticles for hepatocyte-delivery of oridonin, Int. J. Pharm. 2016, 502, 47–60.
